Therapeutic efficiency and safety assessment of Centella asiatica capsule in patients with non-alcoholic steatohepatitis (NASH) in Thailand

Status

Unknown

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20221215002

Enrollment

Registered

2022-12-15

Start date

2022-12-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult patients with non-alcoholic steatohepatitis (NASH) in Thailand Nonalcoholic Fatty Liver Disease

Interventions

Centella asiatica capsule ,Placebo capsule

Experimental Drug,Placebo Comparator Drug

Centella asiatica ,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1). Age 18 years or more 2).Diagnosed with NASH based on clinical features and abdominal imaging

Exclusion criteria

Exclusion criteria: 1). Not willing to participate to the study 2). Currently on other medications in treating NASH 3).Severe liver disease 4).Severe renal disease 5).Allergic to Centella asiatica 6).Pregnancy or lactation 7).Alcohol drinking (>21 standard drinks/week in males, or >14 standard drinks in females)

Design outcomes

Primary

Measure	Time frame
alanine aminotransferase (ALT) 6 months U/L	—

Secondary

Measure	Time frame
Clinical adverse reactions 6 months Clinical adverse reactions,Blood chemistry 6 months Blood chemistry,6. Upper abdominal ultrasound 6 months Imaging profiles	—

Countries

Thailand

Contacts

Public ContactWeeratian Tawanwongsri

Walailak University

weeratian.ta@gmail.com075673082

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026